A5072017521- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Cancer Immunotherapy and Biomarkers
- Machine Learning in Bioinformatics
- Venomous Animal Envenomation and Studies
- HER2/EGFR in Cancer Research
- RNA Interference and Gene Delivery
- Childhood Cancer Survivors' Quality of Life
- Psoriasis: Treatment and Pathogenesis
- Renal and related cancers
- Autoimmune Neurological Disorders and Treatments
- Neuroscience and Neuropharmacology Research
- Autoimmune and Inflammatory Disorders Research
- Reproductive System and Pregnancy
- Monoclonal and Polyclonal Antibodies Research
- Epilepsy research and treatment
- Radiopharmaceutical Chemistry and Applications
- Immune Response and Inflammation
- Erythrocyte Function and Pathophysiology
- Hematopoietic Stem Cell Transplantation
- Nanoplatforms for cancer theranostics
- Neurogenetic and Muscular Disorders Research
Mater Research
2015-2024
The University of Queensland
2015-2024
Translational Research Institute
2016-2024
Monash University
2019
Dendritic cells (DC) initiate the differentiation of CD4+ helper T into effector including Th1 and Th17 responses that play an important role in inflammation autoimmune disease pathogenesis. In mice, are regulated by different conventional (c) DC subsets, with cDC1 being main producers IL-12p70 inducers responses, whilst cDC2 produce IL-23 to promote responses. The human subsets memory cell activation is not known. This study investigated production promoting cytokine IL-12p70, cytokines,...
DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined other therapies. Targeting vaccine antigens (Ag) directly DCs in vivo is more effective than cell-based therapies mouse models therefore a promising strategy translate humans. The human CD141+ considered most clinically relevant initiating CD8+ critical killing tumors or infected cells, they specifically express C-type lectin-like...
Cross-presentation is the mechanism by which exogenous Ag processed for recognition CD8(+) T cells. Murine CD8α(+) DCs are specialized at cross-presenting soluble and cellular Ag, but in humans this process poorly characterized. In study, we examined uptake cross-presentation of human blood CD141(+) DCs, equivalent mouse compared them with monocyte-derived (MoDCs) CD1c(+) DC subsets. MoDCs were superior their capacity to internalize cross-present protein whereas more efficient ingesting Ag....
Background The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of checkpoint inhibitor (ICI) therapies in animal models but little known about role human CD141 + DC cDC1 equivalent patients with melanoma. Methods We developed a flow cytometry assay to quantify characterize blood subsets healthy donors stage 3 4 metastatic To examine whether harnessing DCs could improve ICIs melanoma, we humanized mouse model by engrafting...
Human immune cell subsets develop in immunodeficient mice following reconstitution with human CD34+ hematopoietic stem cells. These "humanized" are useful models to study immunology and human-tropic infections, autoimmunity, cancer. However, some unable fully or acquire full functional capacity due a lack of cross-reactivity many growth factors cytokines between species. Conventional dendritic cells (cDCs) categorized into cDC1, which mediate T helper (Th)1 CD8+ responses, cDC2, Th2 Th17...
Mice reconstituted with human hematopoietic stem cells are valuable models to study aspects of the immune system in vivo. We describe a humanized mouse model (hu mice) which fully functional CD141+ and CD1c+ myeloid CD123+ plasmacytoid dendritic (DC) develop from cord blood CD34+ immunodeficient mice. DC equivalents murine CD8+ /CD103+ essential for induction tumor-inhibitory cytotoxic T lymphocyte responses, making them attractive targets exploit development new cancer immunotherapies. used...
Abstract Objectives Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8 + T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141 dendritic (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclusively DCs regulates T‐cell responses. We developed a new vaccine comprising human anti‐CLEC9A antibody fused investigated its capacity target activate naïve memory WT1‐specific cells. Methods was...
Background Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness key cDC1 subtype required effective CD8 + T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery immunogenic antigens to CD141 DCs, human equivalent. DCs exclusively express C-type-lectin-like receptor CLEC9A, which is important regulation T cell This study developed a new vaccine that harnesses anti-CLEC9A antibody specifically...
Growing interest surrounds adoptive cellular therapies utilizing Natural Killer (NK) cells, which can be obtained from various sources, including umbilical cord blood (UCB) and adult peripheral (APB). Understanding NK cell receptor expression diversity in such sources will guide future therapeutic designs. We used a 20-color flow cytometry panel to compare unstimulated cytokine-activated UCB APB cells. Our analysis showed that cells express slightly higher levels of the immune checkpoints...
Abstract DEC-205 is a cell-surface receptor that transports bound ligands into the endocytic pathway for degradation or release within lysosomal endosomes. This has been reported to bind number of ligands, including keratin, and some classes CpG oligodeoxynucleotides (ODN). In this study, we explore in detail requirements binding ODNs, revealing efficiently binds single-stranded, phosphorothioated ODN ≥14 bases, with preference DNA base thymidine, but no requirement motif. fails...
Background: Dendritic cells (DC) are a heterogeneous cell population, with specialist subtypes driving specific immune responses. In mice, the cDC1 subset (also referred to as Batf3-dependent DC, XCR1+ CD8+ DC in lymphoid tissues and CD103+ peripheral tissues) is essential for induction of tumour responses efficacy checkpoint inhibitor blockade adoptive T immunotherapies. Vaccines that can deliver antigens (Ag) directly DCs vivo more effective than cell-based therapies mouse models promising...
Abstract Objectives Immunotherapies targeting natural killer (NK) cell receptors have shown promise against leukaemia. Unfortunately, cancer immunosuppressive mechanisms that alter NK phenotype prevent such approaches from being successful. The study utilises advanced cytometry to examine how pathways affect phenotypic changes in clinical samples. Methods In this study, we conducted a high‐dimensional examination of the surface expression 16 paediatric patients with acute myeloid leukaemia...
<h3>Background</h3> Dendritic cells (DC) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness key cDC1 subtype required effective CD8+ T cell mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery immunogenic antigens to CD141+ DC, human equivalent. DC exclusively express C-type-lectin-like receptor CLEC9A, which is important regulation This study developed a new vaccine that harnesses anti-CLEC9A antibody specifically...
Abstract Dendritic cells (DC) are a heterogeneous cell population, with specialist subtypes driving specific immune responses. In mice, the cDC1 subset (also referred to as Batf3-dependent DC, XCR1+ CD8+ DC in lymphoid tissues and CD103+ peripheral tissues) is essential for induction of tumor responses efficacy checkpoint inhibitor blockade adoptive T-cell immunotherapies. Vaccines that can deliver antigens (Ag) directly DCs vivo more effective than cell-based therapies mouse models...
Abstract Dendritic cells (DCs) as professional antigen-presenting with unique T-cell stimulatory capacity represent a potential means by which to improve response rates towards immune checkpoint inhibitor antibodies (ICIs) such anti-PD-1 (pembrolizumab) in melanoma. The conventional type 1 DC subset (cDC1) is indispensable for the efficacy of ICIs animal models; however, very little known about role cDC1 human cancer patients. To address this, we developed whole-blood assay quantifying and...